



€130 Million
Private Placement



Lead Placement Agent
February 2023

SVB Securities Serves as Lead Placement Agent for Abivax's (Euronext Paris: ABVX) €130 Million Private Placement

Key Transaction Highlights

- On February 22, 2023, Abivax announced a €130 million private placement.
- Well oversubscribed from both new and existing investors
- Deal consisted of 20,000,000 ordinary shares at a public offering price of €6.50 per share, pricing at market on February 22, 2023.
- Abivax intends to use net proceeds from the financing primarily to further advance the cibefactimod pivotal Phase 3 clinical trial program in ulcerative colitis, as well as for R&D, working capital and other general purposes.
- This financing was led by TCGX, with participation from existing investors Invisus, Deep Track Capital, Sofinova Partners, Venrock Healthcare Capital Partners, as well as from new investors Great Point Partners, LLC, Deerfield Management Company, Commodore Capital, Samsara BioCapital, Boxer Capital and others.
- This is SVB Securities' 1st equity transaction for Abivax.

If you would like to receive this Non-Public Distribution, click [here](#). If you would like to receive this item at SVB Securities Distribution, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED, FOR OR RESENTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL AND IS NOT SOLICITING AN OFFER TO BUY ANY SECURITIES.

BOSTON
60 State Street
4th Floor
Boston, MA 02109

CHARLOTTE
2121 Ruckelshaus Street
Suite 100
Charlotte, NC 28203

KNOXVILLE
47 Sargent 18th Boulevard
Suite 200
Knoxville, TN 37919

NEW YORK
1001 Avenue of the Americas
10th Floor
New York, NY 10019

SAN FRANCISCO
300 California Street
10th Floor
San Francisco, CA 94111